Header Logo

Connection

Kim Steegen to Genotype

This is a "connection" page, showing publications Kim Steegen has written about Genotype.
Connection Strength

0,999
  1. K103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to Doravirine. Viruses. 2024 Sep 20; 16(9).
    View in: PubMed
    Score: 0,208
  2. Feasibility and clinical relevance of HIV-1 drug resistance testing in patients with low-level viraemia in South Africa. J Antimicrob Chemother. 2021 09 15; 76(10):2659-2665.
    View in: PubMed
    Score: 0,169
  3. Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey. PLoS One. 2016; 11(12):e0166305.
    View in: PubMed
    Score: 0,121
  4. HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa. J Antimicrob Chemother. 2017 01; 72(1):210-219.
    View in: PubMed
    Score: 0,119
  5. High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa. PLoS One. 2015; 10(2):e0118145.
    View in: PubMed
    Score: 0,107
  6. A sensitive in-house RT-PCR genotyping system for combined detection of plasma HIV-1 and assessment of drug resistance. J Virol Methods. 2006 May; 133(2):137-45.
    View in: PubMed
    Score: 0,057
  7. Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir. Viruses. 2024 12 06; 16(12).
    View in: PubMed
    Score: 0,053
  8. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study. Lancet HIV. 2018 11; 5(11):e638-e646.
    View in: PubMed
    Score: 0,034
  9. Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. EBioMedicine. 2017 Apr; 18:225-235.
    View in: PubMed
    Score: 0,031
  10. Viral tropism and antiretroviral drug resistance in HIV-1 subtype C-infected patients failing highly active antiretroviral therapy in Johannesburg, South Africa. AIDS Res Hum Retroviruses. 2014 Mar; 30(3):289-93.
    View in: PubMed
    Score: 0,025
  11. A pragmatic approach to HIV-1 drug resistance determination in resource-limited settings by use of a novel genotyping assay targeting the reverse transcriptase-encoding region only. J Clin Microbiol. 2013 Jun; 51(6):1757-61.
    View in: PubMed
    Score: 0,023
  12. A synthetic HIV-1 subtype C backbone generates comparable PR and RT resistance profiles to a subtype B backbone in a recombinant virus assay. PLoS One. 2011; 6(5):e19643.
    View in: PubMed
    Score: 0,021
  13. Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1. Antimicrob Agents Chemother. 2009 May; 53(5):2185-8.
    View in: PubMed
    Score: 0,018
  14. Optimization of a genotypic assay applicable to all human immunodeficiency virus type 1 protease and reverse transcriptase subtypes. J Virol Methods. 2005 Sep; 128(1-2):47-53.
    View in: PubMed
    Score: 0,014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.